Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy. / Bohr, Adam; Nascimento, Thais Leite; Harmankaya, Necati; Weisser, Johan Juhl; Wang, Yingya; Grohganz, Holger; Rades, Thomas; Löbmann, Korbinian.

In: Molecules, Vol. 24, No. 2, 266, 2019.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Bohr, A, Nascimento, TL, Harmankaya, N, Weisser, JJ, Wang, Y, Grohganz, H, Rades, T & Löbmann, K 2019, 'Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy', Molecules, vol. 24, no. 2, 266. https://doi.org/10.3390/molecules24020266

APA

Bohr, A., Nascimento, T. L., Harmankaya, N., Weisser, J. J., Wang, Y., Grohganz, H., ... Löbmann, K. (2019). Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy. Molecules, 24(2), [266]. https://doi.org/10.3390/molecules24020266

Vancouver

Bohr A, Nascimento TL, Harmankaya N, Weisser JJ, Wang Y, Grohganz H et al. Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy. Molecules. 2019;24(2). 266. https://doi.org/10.3390/molecules24020266

Author

Bohr, Adam ; Nascimento, Thais Leite ; Harmankaya, Necati ; Weisser, Johan Juhl ; Wang, Yingya ; Grohganz, Holger ; Rades, Thomas ; Löbmann, Korbinian. / Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy. In: Molecules. 2019 ; Vol. 24, No. 2.

Bibtex

@article{5533bc5fd9294ce296daf23adc46cbec,
title = "Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy",
author = "Adam Bohr and Nascimento, {Thais Leite} and Necati Harmankaya and Weisser, {Johan Juhl} and Yingya Wang and Holger Grohganz and Thomas Rades and Korbinian L{\"o}bmann",
year = "2019",
doi = "10.3390/molecules24020266",
language = "English",
volume = "24",
journal = "Molecules",
issn = "1420-3049",
publisher = "M D P I AG",
number = "2",

}

RIS

TY - JOUR

T1 - Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy

AU - Bohr, Adam

AU - Nascimento, Thais Leite

AU - Harmankaya, Necati

AU - Weisser, Johan Juhl

AU - Wang, Yingya

AU - Grohganz, Holger

AU - Rades, Thomas

AU - Löbmann, Korbinian

PY - 2019

Y1 - 2019

U2 - 10.3390/molecules24020266

DO - 10.3390/molecules24020266

M3 - Journal article

C2 - 30642009

VL - 24

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 2

M1 - 266

ER -

ID: 211863219